Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares stood at 3.53 million during the last session, with the company’s beta value hitting 0.69. At the close of
Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares stood at 43.67 million during the last session, with the company’s beta value hitting 0.68. At the close of
In the last trading session, 2.07 million Viracta Therapeutics Inc (NASDAQ:VIRX) shares changed hands as the company’s beta touched 0.69. With the company’s per share
During the last session, Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares were 0.54 million, with the beta value of the company hitting 0.71. At the end
Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares stood at 1.15 million during the last session, with the company’s beta value hitting 0.71. At the close of
Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares stood at 0.6 million during the last session, with the company’s beta value hitting 0.71. At the last check
Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares stood at 1.0 million during the last session, with the company’s beta value hitting 0.73. At the close of
In last trading session, Viracta Therapeutics Inc (NASDAQ:VIRX) saw 10.97 million shares changing hands with its beta currently measuring 0.76. Company’s recent per share price
During the last session, Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares were 0.42 million, with the beta value of the company hitting 0.72. At the end
In the last trading session, 2.17 million shares of the Viracta Therapeutics Inc (NASDAQ:VIRX) were traded, and its beta was 0.71. Most recently the company’s
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
